These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 15803823)
1. [Hyperhomocysteinemia as a clinical manifestation of thrombosis risk]. Kozlova TV Klin Med (Mosk); 2005; 83(2):9-12. PubMed ID: 15803823 [No Abstract] [Full Text] [Related]
5. Murine models of hyperhomocysteinemia and their vascular phenotypes. Dayal S; Lentz SR Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1596-605. PubMed ID: 18556571 [TBL] [Abstract][Full Text] [Related]
6. [Hyperhomocysteinaemia: physiopathology and medical implications]. Torre Delgadillo A; Téllez Zenteno JF; Morales Buenrrostro LE Rev Invest Clin; 2000; 52(5):557-64. PubMed ID: 11195184 [TBL] [Abstract][Full Text] [Related]
7. Hyperhomocysteinemia and lower extremity wounds. Schwartzfarb EM; Romanelli P Int J Low Extrem Wounds; 2008 Sep; 7(3):126-36. PubMed ID: 18757388 [TBL] [Abstract][Full Text] [Related]
8. Impact of hypertension and hyperhomocysteinemia on arterial thrombosis in primary antiphospholipid syndrome. de Souza AW; Silva NP; de Carvalho JF; D'Almeida V; Noguti MA; Sato EI Lupus; 2007; 16(10):782-7. PubMed ID: 17895300 [TBL] [Abstract][Full Text] [Related]
9. Pro-thrombotic and pro-oxidant effects of diet-induced hyperhomocysteinemia. Sauls DL; Arnold EK; Bell CW; Allen JC; Hoffman M Thromb Res; 2007; 120(1):117-26. PubMed ID: 16979225 [TBL] [Abstract][Full Text] [Related]
10. Genetic determinants of plasma total homocysteine. Gellekink H; den Heijer M; Heil SG; Blom HJ Semin Vasc Med; 2005 May; 5(2):98-109. PubMed ID: 16047263 [TBL] [Abstract][Full Text] [Related]
11. Neurological implications of hyperhomocysteinemia in patients with atherothrombotic disease. Tanne D; Sela BA Ital Heart J; 2003 Sep; 4(9):577-9. PubMed ID: 14635373 [No Abstract] [Full Text] [Related]
12. Hyperhomocysteinemia: clinical and therapeutical involvement in venous thrombosis. Hoţoleanu C; Porojan-Iuga M; Rusu ML; Andercou A Rom J Intern Med; 2007; 45(2):159-64. PubMed ID: 18333369 [TBL] [Abstract][Full Text] [Related]
13. Hyperhomocysteinemia and the compound heterozygous state for methylene tetrahydrofolate reductase are independent risk factors for deep vein thrombosis among South Indians. Naushad S; Jamal NJ; Angalena R; Prasad CK; Devi AR Blood Coagul Fibrinolysis; 2007 Mar; 18(2):113-7. PubMed ID: 17287626 [TBL] [Abstract][Full Text] [Related]
14. [Should we consider hyperhomocysteinemia as a vascular risk factor?]. Quéré I Rev Med Interne; 2000 Mar; 21(3):229-30. PubMed ID: 10763182 [No Abstract] [Full Text] [Related]
15. Are homocysteine and MTHFR genotype polymorphism associated with arteriovenous fistula patency? Tai HC; Yang WC; Chen TW; Lin CC Am J Kidney Dis; 2005 Nov; 46(5):993-4; author reply 994. PubMed ID: 16253747 [No Abstract] [Full Text] [Related]
16. Homocysteine as atherothrombotic agent: is the bark worse than the bite? Ubbink JB; Delport R Nutrition; 2000; 16(7-8):672-4. PubMed ID: 10906593 [No Abstract] [Full Text] [Related]
17. Homocysteine, intracellular signaling and thrombotic disorders. Dionisio N; Jardín I; Salido GM; Rosado JA Curr Med Chem; 2010; 17(27):3109-19. PubMed ID: 20629621 [TBL] [Abstract][Full Text] [Related]
18. The risk of venous and arterial thrombosis in hyperhomocysteinemic subjects may be a result of elevated factor VIII levels. Lijfering WM; Veeger NJ; Brouwer JL; van der Meer J Haematologica; 2007 Dec; 92(12):1703-6. PubMed ID: 18055997 [TBL] [Abstract][Full Text] [Related]
19. [Hyperhomocysteinemia--one of the factors underlying thrombotic complications in patients with chronic myeloproliferative diseases]. Sokolova MA; Khoroshko ND; Tsvetaeva NV; Turkina AG; Levina AA; Mamukova IuI; Rokhnianskaia AA; Sudarikov AB; Romanova EA; Vasil'ev SA; Sukhanova GA; Orel EB; Rudakova VE; Tutaeva VV; Manakova TE; Semenova EA; Kulikov SM Ter Arkh; 2007; 79(12):57-62. PubMed ID: 18220034 [TBL] [Abstract][Full Text] [Related]